Filtered By:
Condition: Heart Failure
Therapy: Dialysis

This page shows you your search results in order of relevance. This is page number 14.

Order by Relevance | Date

Total 251 results found since Jan 2013.

Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials
CONCLUSIONS: Roxadustat was more effective than placebo at increasing hemoglobin in patients with non-dialysis-dependent CKD and anemia, while decreasing transfusion rate and being noninferior to placebo with respect to risk of MACE.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: A Study of FG-4592 for the Treatment of Anemia in Chronic Kidney Disease Patients Not Receiving Dialysis, NCT01750190; Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS), NCT01887600; Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not ...
Source: Clinical Journal of the American Society of Nephrology : CJASN - August 7, 2021 Category: Urology & Nephrology Authors: Robert Provenzano Lynda Szczech Robert Leong Khalil G Saikali Ming Zhong Tyson T Lee Dustin J Little Mark T Houser Lars Frison John Houghton Thomas B Neff Source Type: research

Acute kidney injury and risk of cardiovascular outcomes: A nationwide cohort study
CONCLUSION: Non-selected patients aged 50 years or above with AKI during admission had significantly higher one-year risk of cardiovascular event or death, especially, but not only due to heart failure, independent of age and eGFR.PMID:34489123 | DOI:10.1016/j.nefro.2021.06.007
Source: Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia - September 7, 2021 Category: Urology & Nephrology Authors: Philip Andreas Schytz Paul Blanche Anders Bonde Nissen Christian Torp-Pedersen Gunnar H Gislason Karl Emil Nelveg-Kristensen Kristine Hommel Nicholas Carlson Source Type: research

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
ConclusionRoxadustat improved hemoglobin similarly to ESA while demonstrating comparable cardiovascular and overall safety profiles in a wide spectrum of dialysis-dependent patients with anemia of CKD. Roxadustat represents an oral alternative to ESAs for achieving a target hemoglobin for anemia of CKD in dialysis-dependent patients.
Source: Advances in Therapy - September 14, 2021 Category: Drugs & Pharmacology Source Type: research

Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target
Chronic kidney disease (CKD) is present in almost 10% of the world population and is associated with excess mortality and morbidity. Reduced glomerular filtration rate and the presence and extent of proteinuria, key domains of CKD, have both been shown to be strong and independent risk factors for cardiovascular disease. Patients with kidney failure requiring dialysis are at highest risk for cardiovascular events, for example, stroke or myocardial infarction, and of developing chronic cardiovascular conditions, such as heart failure.
Source: Kidney International - September 30, 2021 Category: Urology & Nephrology Authors: John Eikelboom, J ürgen Floege, Ravi Thadhani, Jeffrey I. Weitz, Wolfgang C. Winkelmayer Tags: review Source Type: research

MILLER Banding Procedure for Treatment of Dialysis Access-Related Steal Syndrome, Pulmonary Hypertension, and Heart Failure
Am Surg. 2021 Nov 18:31348211056259. doi: 10.1177/00031348211056259. Online ahead of print.ABSTRACTA Minimally Invasive Limited Ligation Endoluminal-assisted Revision (MILLER) banding procedure has been used for treating patients with dialysis access-related steal syndrome (DASS) and high-flow vascular access-related pulmonary hypertension (PHT) and heart failure (HF).We performed a retrospective analysis of patients undergoing the MILLER procedure performed for DASS, HF, and PHT from our Vascular Access Database from September 2017 to October 2019. Outcomes included primary patency of banding, primary assisted patency, an...
Source: The American Surgeon - November 19, 2021 Category: Surgery Authors: Ahmad Alqassieh Patrick B Dennis Veena Mehta June Shi Angello Lin Dave Taber Vinayak Rohan Source Type: research

Association of peridialytic, intradialytic, scheduled interdialytic and ambulatory BP recordings with cardiovascular events in hemodialysis patients
CONCLUSIONS: Averaged intradialytic and scheduled home BP measurements (but not pre-dialysis readings) display similar prognostic associations with 44-h ambulatory BP in hemodialysis patients and represent valid metrics for hypertension management in these individuals.PMID:34988941 | DOI:10.1007/s40620-021-01205-9
Source: Journal of Nephrology - January 6, 2022 Category: Urology & Nephrology Authors: Fotini Iatridi Marieta P Theodorakopoulou Antonios Karpetas Athanasios Bikos Artemios G Karagiannidis Maria-Eleni Alexandrou Ioannis Tsouchnikas Christopher C Mayer Anna-Bettina Haidich Aikaterini Papagianni Gianfranco Parati Pantelis A Sarafidis Source Type: research

Impact of left ventricular hypertrophy on clinical outcomes in patients with dialysis: a single-center study in Japan
ConclusionJapanese patients with LVH undergoing dialysis had a worse prognosis than those without LVH in terms of the composite clinical endpoint.
Source: Journal of Medical Ultrasonics - March 17, 2022 Category: Radiology Source Type: research

Extent of mural thrombus is not associated with increased 5-year mortality following elective AAA repair
CONCLUSIONS: In our experience, the extent of mural thrombus in AAA does not influence long-term survival after elective repair. AAA repair may provide protection against circulating components of mural thrombus which have the potential to promote atherosclerotic-related adverse events. Patients with renal insufficiency and larger AAA have increased risk of mortality 5 years after elective repair.PMID:35331063 | DOI:10.1177/17085381211063282
Source: Vascular - March 25, 2022 Category: Surgery Authors: Bilal Siddiq Matthew Dejong Emily Decicco Tara Zielke Melissa D'Andrea Bernadette Aulivola Matthew Blecha Source Type: research

CZecking heart failure in patients with advanced chronic kidney disease (Czech HF-CKD): Study protocol
DISCUSSION: This trial will differ from others by: (1) detailed repeated hemodynamic assessment including arteriovenous access flow and (2) by careful assessment of adequate hydration to avoid confusion between HF and water overload.PMID:35676802 | DOI:10.1177/11297298221099843
Source: The Journal of Vascular Access - June 9, 2022 Category: Surgery Authors: Jan Malik Anna Valerianova Satu Sinikka Pesickova Zdenka Hruskova Vladimira Bednarova Pavel Michalek Vladimir Polakovic Vladimir Tesar Source Type: research

Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease
CONCLUSIONS: HIF stabiliser management of anaemia had uncertain effects on CV death, fatigue, death (any cause), CV outcomes, and kidney failure compared to placebo or ESAs. Compared to placebo or ESAs, HIF stabiliser management of anaemia probably decreased the proportion of patients requiring blood transfusions, and probably increased the proportion of patients reaching the target Hb when compared to placebo.PMID:36005278 | DOI:10.1002/14651858.CD013751.pub2
Source: Cochrane Database of Systematic Reviews - August 25, 2022 Category: General Medicine Authors: Patrizia Natale Suetonia C Palmer Allison Jaure Elisabeth M Hodson Marinella Ruospo Tess E Cooper Deirdre Hahn Valeria M Saglimbene Jonathan C Craig Giovanni Fm Strippoli Source Type: research